To include your compound in the COVID-19 Resource Center, submit it here.

Swift approval for Zelboraf, companion test

FDA approved melanoma drug Zelboraf vemurafenib and its companion BRAF V600 Mutation Test on Wednesday, well ahead of the products' respective action

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE